Journal Scans
Phase II trial of Modified FOLFOX6 and Erlotinib in Patients With Metastatic or Advanced Adenocarcinoma of the Oesophagus and Gastro-Oesophageal Junction
FOLFOX6 + Erlotinib Promising for Esophageal/GE Junction Adenocarcinoma
ZA Wainberg, LS Lin, B Dicarlo, KM Dao, R Patel, DJ Park, HJ Wang, R Elashoff, N Ryba, JR Hecht
20110702
2011 Aug 2
Br J Cancer
Phase II trial of Modified FOLFOX6 and Erlotinib in Patients With Metastatic or Advanced Adenocarcinoma of the Oesophagus and Gastro-Oesophageal Junction
Br J Cancer. 2011 Aug 2;105(6):760-765, ZA Wainberg, LS Lin, B Dicarlo, KM Dao, R Patel, DJ Park, HJ Wang, R Elashoff, N Ryba, JR Hecht
TAKE-HOME MESSAGE
Abstract
Abstract
Background: There is increased recognition that cancers of the upper GI tract comprise distinct epidemiological and molecular entities. Erlotinib has shown activity in patients with adenocarcinoma of the oesophagus/gastro-oesophageal junction (GEJ), but not in distal gastric cancer. mFOLFOX6 is one of several active regimens used to treat adenocarcinoma of the Eso/GEJ. This study evaluates the efficacy and safety of mFOLFOX6 and erlotinib in patients with metastatic or advanced Eso/GEJ cancers.Methods:...
